Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Why Is UroGen Pharma Ltd. (URGN) Stock Up +8.21% Today?

Why Is UroGen Pharma Ltd. (URGN) Stock Up +8.21% Today?

Key Takeaways

  • UroGen Pharma Ltd. (URGN) traded at $28.33, up $2.15 or 8.21%, from the prior close of $26.18 — after opening the session 8% lower.
  • The primary catalyst was a competitive read-through: CG Oncology (CGON) reported positive Phase 3 bladder-cancer data before the open, hitting bladder-cancer names first and then reversing.
  • Secondary drivers: a deeply oversold chart, heavy short interest, and a shareholder base already braced for bad news after a brutal two-week slide.
  • Broader context: the swing was concentrated in the NMIBC niche rather than macro — CGON rallied roughly 14% while URGN reversed from a double-digit early decline.
  • News Significance Score: 42/100 - A moderate rival-trial read-through met a move about 3.5 times the stock's typical daily swing.
  • What traders are watching next: the December 2 scientific presentation of the rival dataset, UGN-103's June 14, 2027 PDUFA date, and fourth-quarter ZUSDURI revenue trends.
  • Deeper detail on Price Targets, Earnings and Forecast is available on dedicated ticker pages.
  • Readers can also explore Trending AI Robots for live bot performance across thousands of symbols.

Opening Summary

UroGen Pharma Ltd. (URGN) is a Princeton, New Jersey-based biotech that uses its RTGel sustained-release hydrogel platform to turn standard chemotherapy agents into gels that can be instilled directly into the urinary tract, allowing tumors to be treated without surgery. Its commercial portfolio includes ZUSDURI, approved for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (NMIBC), and JELMYTO for low-grade upper tract urothelial cancer. Shares were trading at $28.33 in the afternoon, up $2.15, or 8.21%, from the previous close of $26.18. The direction is firmly higher, but the path was not: the stock opened at $24.00 and touched $23.19 before reversing. The immediate driver was an intraday reassessment of a rival's clinical win in the same disease area.

The CG Oncology Read-Through

Before the opening bell, CG Oncology (CGON) announced topline results from its Phase 3 PIVOT-006 trial of cretostimogene in intermediate-risk and high-grade Ta NMIBC following complete tumor resection. The trial met its primary endpoint, cutting the risk of recurrence by 68% versus surveillance with a hazard ratio of 0.32 and no grade 3 or higher treatment-related adverse events.

The market's first reaction was to sell the incumbent. URGN gapped down to $24.00 and fell as far as $23.19, roughly 11% below Friday's close, on the assumption that a well-tolerated rival with a compelling recurrence benefit would erode ZUSDURI's addressable market in intermediate-risk disease.

Why Sellers Lost Control of the Tape

The reversal came as investors worked through the clinical and regulatory detail. Cretostimogene is an adjuvant therapy given after transurethral resection, while ZUSDURI is positioned as a primary, surgery-free treatment that replaces a TURBT rather than following one — so PIVOT-006 compared the rival agent against surveillance, not against UroGen's product. No head-to-head data exists, and the rival's filing in intermediate-risk disease is not expected before the second quarter of 2027, with approval unlikely before 2028.

Company fundamentals also argued against panic. ZUSDURI generated $68.0 million in the third quarter, up 35% sequentially, with 662 unique prescribers and repeat prescribers now half of total writers. Management continues to guide toward profitability and positive cash flow in the fourth quarter. Consensus analyst targets cluster near $60, far above the market price, and short interest of roughly 5.1 million shares created fuel for covering once the early selling stalled. With the stock already down about 48% from its August high of $50.81, the setup favored a sharp countertrend bounce.

Market Context and Trading Activity

Volume was clearly elevated: roughly 1.8 million shares had changed hands by mid-afternoon against a three-month average near 1.0 million and recent sessions that frequently printed under 500,000. The intraday range from $23.19 to $29.50 spanned about 24% of Friday's close, a signature of forced positioning rather than gradual repricing.

The divergence within the group was the day's defining feature — CGON surged on its own data while URGN absorbed the initial blow and then rallied. Technically, the rebound is still a bounce inside a downtrend: the stock remains below its 20-, 50- and 200-day moving averages, all of which sit in the $31–$40 area and represent overhead supply.

News Significance Score

The score runs from 0, meaning no meaningful news and a move entirely normal for the stock, to 100, meaning transformative news paired with an extreme, rare price move. URGN lands at 42 out of 100. The catalyst was moderate and indirect: a rival's Phase 3 success redraws the competitive map but is not UroGen's own data, and it carries no near-term revenue impact. The 8.21% advance was roughly 3.5 times the stock's average absolute daily move of about 2.3% across the last 60 sessions, and moves of that magnitude occurred only three times in that window. Elevated volume and a wide intraday range support the upper half of that band, and together the two factors produce a mid-range score.

What Comes Next for URGN

Attention turns to the fourth-quarter report, expected in early 2027, when investors will test management's pledge of quarterly profitability and positive cash flow on roughly $90.5 million of cash. Sequentially, ZUSDURI growth and holiday seasonality in patient starts will be scrutinized, along with JELMYTO trends after guidance was trimmed to about $90 million for 2026. On the pipeline, UGN-103 has a PDUFA goal date of June 14, 2027, the LONGVIEW-HR study is slated to begin in the fourth quarter, and UGN-104 enrollment is expected to complete around year-end or early 2027. Direct-to-consumer promotion ramps in 2027. Key risks include slower urologist adoption, reimbursement friction, a heavily indebted balance sheet, and the eventual arrival of new competition in intermediate-risk disease.

Trending AI Robots

Tickeron's Trending AI Robots page curates the strongest-performing automated strategies under current market conditions from a library of hundreds of AI trading bots covering thousands of tickers. Because bots differ widely by strategy, holding period, risk profile, performance metrics and the symbols they trade, the trending list is a useful starting point for comparing approaches side by side. Volatile names like this one often appear in those strategies. Readers can review the current leaders and assess which fits their own objectives.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: URGN

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


URGN in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 04, 2026

URGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 36 cases where URGN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where URGN's RSI Indicator exited the oversold zone, 25 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where URGN advanced for three days, in 213 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on URGN as a result. In 68 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

The Moving Average Convergence Divergence Histogram (MACD) for URGN turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 35 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where URGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for URGN entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.138) is normal, around the industry mean (3.586). P/E Ratio (-12.563) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (11.403) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. URGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. URGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -10%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -22%. PEPG experienced the highest price growth at 75%, while ALGS experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapies for urological pathologies

Industry Biotechnology

Industry
Biotechnology
Address
400 Alexander Park Drive
Phone
+1 646 768-9780
Employees
291
Web
https://www.urogen.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.